Frontier Milestones Invest BETA
EN KO
☰
Not investment advice · Market data delayed ≥ 15 min · Technical data last verified 2026-06-22 · No ratings, price targets or buy / sell signals are shown
← Screener

Neuracle

Brain-Computer Interfaces·Private
Tech Score51EmergingOPINION
Goal milestone FDA-approved commercial brain-computer interface

Shanghai BCI maker whose semi-invasive NEO implant (with Tsinghua) won the world's first commercial approval for an invasive-class BCI (NMPA, 2026).

HQShanghai, China Websitewww.neuracle.cn ↗

Technology ↔ market gap

Verified technical progress over time. Market valuation overlays once delayed data connects.

Technical progress Market valuation
1 2 3 4 5 Current 3.0

Trajectory builds as milestones accumulate.

Verified stage
3.0 / 5
05
Market-impliedAwaiting market data
GapOPINIONAwaiting market data

Catalysts

Stock-moving events from the newsroom feed — facts, not advice. No rating, no price target.

2026-07-15
Commercialization
World first: a commercial brain-computer interface is implanted in a paying patient
source · Gizmodo ↗ read ↗

Technical milestones

Verified progress on the Frontier Milestones tracker ↗

From the verified Frontier Milestones dataset.

2026-03
Stage 3
World's first commercial invasive-BCI approval
source ↗
2026-07-13
World's first commercial BCI implanted in a patient
source ↗
Distance to goal 60%
FDA-approved commercial brain-computer interface

Market data

Price, market cap and 52-week range connect with delayed market data.

Quantitative factors

Computed once market data connects (price, market cap, runway).

Commentary

No analyst commentary published yet.

Commentary reflects one analyst’s view and is not a recommendation. It is presented alongside factual data and is explicitly labelled opinion.

Discussion0

Member discussion. Not investment advice, solicitation, or a recommendation.

Loading…
LICENSE-GATED Ratings & price targets are not shown. FM Invest does not display buy / hold / sell ratings or price targets until investment-advisory licensing is in place. The schema exists and is gated to zero exposure until then.

For information only. Not investment advice and not a solicitation. Market data is delayed and provided “as is”; technical data is read from the Frontier Milestones verified dataset.